Drugs / BCD-054
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02359877 | Jul 2014 → Oct 2015 | — | Biocad | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02744222 | Aug 2017 → Nov 2018 | relapsing-remitting multiple sclerosis | Biocad | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02744222 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM” NCT02359877 ↗ |
| Route | Intramuscular | “administrated intramuscular and subcutaneous” NCT02359877 ↗ |
| Route | Subcutaneous | “administrated intramuscular and subcutaneous” NCT02359877 ↗ |